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Received 12 June 2007; received in revised form 4 September 2007; accepted 6 September 2007Abstract The debate on both the appropriateness of allowing healthy women to provide oocytes for research use and
the use of financial incentives is increasingly reduced to a confrontation between ethics, science, and the welfare of women.
It is plausible that the expansion of national and international research efforts, paired with the growing trend toward
liberalizing stem cell research policies, will inevitably result in increased demand for the materials needed to conduct such
research. The scarcity of human reproductive materials that are available for research generates concerns over, the
emergence of a “black market”, an increase in financial incentives for donors, and the appropriateness of current regulatory
frameworks that aim to safeguard donors. In this article we explore the conceptual models for categorizing oocyte donors
and analyze the use of financial incentives as well as the compensation models proposed and implemented in various
jurisdictions. Finally, we propose the adoption of a mixed model that both respects altruism and provides a feasible solution to
an issue that could be situated only in the context of the overall acceptability of providing financial rewards to donors of
human reproductive materials for assisted reproductive technologies.
© 2007 Elsevier B.V. All rights reserved.1 For example, the California Institute of Regenerative Medicine,
Singapore Stem Cell Consortium, the Danish Center for Stem Cell
Research, and the UK Medical Research Council.
2 For example, the International Stem Cell Forum and the
International Society for Stem Cell Research. For a review of theIntroduction
The South Korean scandal regarding fraud and gross ethical
violations in stem cell research, and the resulting decision of
the South Korean National Bioethics Committee to impose
restrictions to such research, has garnered much interna-
tional attention (Kaiser Network Report, 2007). This scandal
has reopened the debate on the appropriateness of allowing
healthy women to provide oocytes for research and on the
use of monetary payments to encourage such donation. As
the South Korean case illustrates, the debate is increasingly⁎ Corresponding author. Fax: +1 514 343 6233.
E-mail address: rosario.isasi@umontreal.ca (R.M. Isasi).
1873-5061/$ – see front matter © 2007 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2007.09.003reduced to a conflict between ethics, science, and the
welfare of women.
It is plausible that the expansion of national1 and
international2 (European Commission Health and Consumer
Protection Directorate General, 2006) stem cell researchEuropean regulatory framework for reproductive cell donation see
European Commission, Health and Consumer Protection Directorate
General’s (2006) Report on the Regulation of Reproductive Cell
Donation in the European Union: Results of Survey. Brussels,
February 2006.
.
5 An analysis of the medical/health risks of oocyte donation for
stem cell research is beyond the scope of this paper. As documented
in the scientific literature, the short- and long-term physiological
and psychological risks are still largely unknown. There is great
4 The term “vendor” was first articulated by Professor George
Annas (Annas, 1980) to reflect the context of commercial sperm
procurement for assisted reproduction.
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stem cell research policies (Isasi and Knoppers, 2006a,
2006b), will inevitably result in increased demand for the
human reproductive materials (Dickenson, 2004) necessary
for such research (Mertes and Pennings, 2007). If alternative
sources of human embryonic stem cell lines do not yield the
promised results, this will undoubtedly be the case (Moore et
al., 2006; Mertes et al., 2006; Schulman, 2005).
The scarcity of human embryos and gametes, particularly
oocytes that are available for research and for the derivation
of stem cell lines, generates various concerns: the possible
emergence of a “black market” (Spar, 2007; Waldby, 2006),
increasing monetary payments for donors3, and the appro-
priateness and sufficiency of current regulatory frameworks
that aim to safeguard donors (Rothman, 2006; Holm, 2006).
The controversial issue of providing monetary payments
for the procurement of human oocytes to be used in stem cell
research must be situated within the larger context of the
donation of other human materials (e.g., blood, organs, and
tissues). Likewise, it must be analyzed in the context of the
overall acceptability of providing financial rewards to donors
or providers of gametes and embryos for assisted reproduc-
tive technologies. Hence, the great challenge before us is to
develop a policy framework that is both ethically and poli-
tically consistent.
It is time to move on from a view that portrays the ex-
ploitation of women or the hampering of scientific progress
as the only ethical and policy options (Katz Rothman, 2006).
An ethically and scientifically sound policy framework
governing the procurement of human reproductive materials
for stem cell research should protect not only donors, but
also broad societal interests such as the advancement of
science. Such a framework could have a substantial impact
on the stem cell research process and on matters such as
donor confidence, transparency, research ethics oversight,
and clarification of the legal rights of donors.
In this article, we will explore the conceptual models for
categorizing the procurement of oocytes for research and
review the use of monetary payments for oocyte donation via
three forms: (a) financial incentives, (b) financial compensa-
tion, and (c) expense reimbursement models.
Oocyte donors, vendors, or providers?
Exploring conceptual models
Different conceptual models potentially apply in the context
of oocyte procurement; they can be distinguished by the
various types of participants and the roles they play. There
are two broad categories: “medical” participants, which en-3 Recently, the UK’s Human Fertilisation and Embryology Author-
ity decided to extend its license to the North East England Stem
Cell Institute (NESCI), allowing the NESCI to recruit egg donations
for somatic cell nuclear transfer research from women undergoing
IVF treatments using an “egg-sharing” program. Under the con-
troversial program part of the patient’s costs for fertility treatment
are covered by the NESCI if the patient agrees to donate a
proportion of the eggs retrieved during the course of the treatment
to the research institute (http://www.hfea.gov.uk/cps/rde/xbcr/
SID-3F57D79B-5E2DA07E/hfea/Variation_of_licence_to_include_
additional_sources_of_eggs_for_research.pdf).compass women already undergoing in vitro fertilization or
other medical interventions (e.g., sterilization), and “non-
medical” participants, which refers to healthy women who
volunteer to undergo medical interventions specifically for
oocyte procurement (Magnus and Cho, 2005).
For any policy framework to be ethically sound, clarity
and accuracy of language are needed to protect against mis-
conceptions. Are participating women vendors, providers, or
donors? The use of monetary payments so as to obtain human
reproductive materials to be used in stem cell research will
be one factor in the determination of the appropriate terms
to be used. When monetary payments are restricted to pro-
viding compensation for financial and personal loss, thereby
precluding financial incentives or any monetary gain to
women providing oocytes, these women are donors in a strict
sense. The term “donor” focuses on the altruistic nature of
the “gift” of biological materials. We must acknowledge,
however, that the term “donor” is in itself ambiguous,
referring as it does both to the motivation of the woman
procuring the oocytes and simply to the situation of no gain.
The point here is that the woman is not better off, financially
or physically, than before donating. The purpose of providing
financial compensation is, then, to offset the donor’s
sacrifice.
In contrast, when significant financial incentives (e.g.,
substantial monetary payments, bonuses, or in-kind services)
are provided in exchange for procuring oocytes, as in the
context of a market model, it is a misnomer to refer to these
women as donors. A more accurate term would be
“vendors,” because of the nature of the financial transac-
tion: these women are delivering a “product” (the oocytes)
for a monetary reward; the transaction mirrors the buying
and selling of products for a profit in the marketplace4.
A third emerging model is one that categorizes healthy
women volunteering to provide oocytes for research pur-
poses (e.g., nonmedical participants) as “research donors.”
This category perhaps best captures the peculiarities of
procuring human oocytes from nonmedical participants, as it
emphasizes the invasive nature of the procurement process,
its potential health risks5, and the fact that women incur
those risks solely for the benefit of others (Mertes et al.,
2006).uncertainty regarding some of the potential acute (e.g., anesthetic
risks, ovarian hyperstimulation syndrome, surgical infections) and
chronic risks (e.g., psychological risks; breast, ovarian, and
endometrial cancer; infertility) of oocyte procurement. In the
absence of sufficient and conclusive studies assessing the outcomes
of women undergoing in vitro fertilization and of oocyte procure-
ment (for both reproductive and research purposes), cautious
strategies that seek to minimize the potential risks to donors are
necessary. Hence, a case-by-case approach with strict selection and
exclusion criteria for donors should be the norm if the safety of
donors is to be the paramount concern (Institute of Medicine and
National Research Council, Committee on Assessing the Medical
Risks of Human Oocyte Donation for Stem Cell Research, 2007).
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volunteer their oocytes for stem cell research expose
themselves to serious medical risks not related to the
research itself, but instead to the procurement process,
and this with no direct benefit for them. Indeed, healthy
volunteers constitute a class of research participants
deserving special consideration. Their close proximity to
the case of oocyte donors for fertility treatments is an
additional factor that warrants the creation of this new
category.
We maintain then that the ethics of oocyte provision for
research is better understood as a form of participation in
human subject research. However, to assess the reason-
ableness of current monetary payment schemes, in such
research, we also need to examine existing compensation
models for the donation of other tissues such as bone
marrow, blood, and biopsies and include factors such as pain,
risk, time, and inconvenience.
The use of monetary payments
The principle of altruism (Titmuss, 1997) has long been an
ethical and regulatory norm governing donation in Western
countries. Altruism is generally understood as the giving to
others without the expectation of receiving a benefit in
return, or as the “devotion to the welfare of others, regard
for others, as a principle of action” (Oxford English Dic-
tionary, 2007). It is entrenched in a long tradition that con-
demns the commodification of the human body and its parts
(Dickenson, 2002). Blood and organ donors epitomize the
ethos of altruism.
An additional underlying ethical issue regarding the
donation of the human body and its parts relates to the
virtue of solidarity. Solidarity holds that individuals should
contribute to the collective good (Chadwick and Berg, 2001).
However, altruism and solidarity do not necessarily oppose
the use of compensation schemes to reimburse donors or
contributors or even the use of monetary payments to
increase the rate of such donations/contributions. An
example of the latter is the European Union’s “Tissue and
Cells Directive” (European Union, 2005a), which, while
upholding the “principle of altruism of the donor and
solidarity between the donor and recipient” and encouraging
unpaid donations, allows for compensation schemes.
Although there is consensus that commercializing or
obtaining financial gains for the donation of human repro-
ductive materials is not permissible (European Union,
2005b),6 divergence exists on various points: what constitu-
tes “reasonable” monetary payment, the conditions under
which payment should be granted, and the type of monetary
payment that is appropriate (e.g., cash or in-kind services).
Moral breach occurs when the line between providing fair
financial compensation to donors or providers and commo-
difying human oocytes is crossed.6 For example, legislation adopted in Australia, Canada, France,
Germany, India, Israel, Italy, Japan, New Zealand, Portugal,
Singapore, South Africa, South Korea, Switzerland, Spain, and the
United Kingdom prohibits commercial transactions related to human
reproduction, including the commercial supply of gametes and
embryos. See also European Union (2005b).Undeniably, the value of the human body and its parts
cannot and should not be expressed in monetary terms. This
does not obviate civil responsibility, which creates the duty
to indemnify where injury to another (and his/her body) was
caused by one’s fault. The inherent moral value of human
reproductive materials—symbolic of human life itself—
situates them outside the economic realm. To treat human
oocytes as merchandise (e.g., by providing monetary
payments for the actual delivery-quantity or quality-of
oocytes: Mertes et al., 2006; Ethics Committee of the
American Society for Reproductive Medicine (ASRM), 2007)
will inevitably undermine fundamental moral, social, cul-
tural, and historical attitudes toward human life in general.
Studies show that financial rewards or monetary pay-
ments are an important motivator among normal healthy
volunteers in their decision to participate in clinical trials
(Tishler and Bartholomae, 2002). Though the evidence is not
conclusive, and the issue has not been systematically and
extensively investigated, it highlights the fact that providing
monetary payments could be ethically problematic. Various
questions remain: do monetary payments lead to greater
risk-taking than altruistic donation/participation? If so, why
are altruistically adopted risks ethically preferable to
financially induced ones? Is it because any monetary payment
is ethically tainted? If exploitation or undue inducement is
avoided, could the monetary payment given to the donor/
participant be morally justified?
Monetary payments present an ethical dilemma because
of the blurred line between what constitutes undue induce-
ment and what does not (Hyun, 2006). Undue inducements
constitute a threat to the individual’s ability to provide free
and voluntary informed consent for donation (Macklin,
1981). Moreover, they hinder the donor’s ability to act in
his or her best interests. An incentive becomes undue
inducement if the donor’s decision to participate rests solely
on the monetary payment (Halpern et al., 2004; Bentley and
Thacker, 2004) or if the incentive blinds the potential donor
to the risks involved in the donation process (Bentley and
Thacker, 2004). To determine what really constitutes undue
or inappropriate inducements, it is not sufficient to look at
the amount of the financial incentive; it is also necessary to
take into account the donor’s social, cultural, economic, and
biographical context. Often, the context in which a donor is
situated determines his or her ability to provide a free,
voluntary, and informed decision in the face of financial
temptation.
Excessive monetary payments may be deemed exploita-
tive and hence incompatible with informed consent (Tishler
and Bartholomae, 2002). It has been argued that the recent
Human Fertilisation and Embryology Authority (HFEA) deci-
sion to allow egg-sharing programs for stem cell research is
tantamount to providing an undue inducement (see contra-
argument, ASRM, 2007). For couples lacking sufficient
financial means to cover the costs of fertility treatments,
participation in the egg-sharing program is the sole way to
have access to such treatments.
The presence of options does not automatically rule out
the possibility of exploitation, because not all choices are
equally free. If the perceived harm of not accepting the
discounted services (e.g., no access to in vitro fertilization
(IVF) treatment) is deemed to be greater than providing
oocytes to researchers, then the situation underlying the
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Consequently, the lack of financial means to cover the IVF
treatment (without participating in the egg-sharing pro-
gram) becomes a potentially manipulative instrument in the
hands of the researchers who provide the “only” alternative.
Excessive control by external influences is not compatible
with voluntary and autonomous decision making and action.
As pointed out, “it is the perceived paucity of other choices,
combined with a sense of desperation or even societal or
familial expectation of how a situation should be resolved
(precisely because the possibility exists) that transforms a
potentially free choice into a coerced act” (Todd, 2001). The
reasons that motivate people to engage in certain activities
matter from a moral and political standpoint. Even if, on
further examination, the egg-sharing scheme licensed by the
HFEA is found to stop short of being exploitative, it remains
undue inducement and thus morally problematic (see HFEA,
2006, for their recent public consultation on the donation of
human oocytes for research purposes). The program also
raises another ethical dilemma: is this type of egg-sharing
program commercialization through the back door?
An ethical analysis of the use of monetary payments for
oocyte donation requires determining the boundaries of their
three distinctive categories (e.g., financial incentives,
financial compensation, and expense reimbursement), so
as to make transparent their ethical dimensions.
Finally, it is important to highlight that in the absence of a
comprehensive and ethically consistent policy framework, or
in the absence of any framework at all, some countries have
de facto adopted a mixed model, whereby the distinctive
categories of monetary payments are combined. In these
jurisdictions, financial incentives (e.g., market model),
financial compensation, and so called “altruistic” contribu-
tions (no-compensation models) coexist with gainful foreign
contributions, as for example, by allowing the importation of
human reproductive materials from countries with a market
model.7 From a political and ethical standpoint, to be in-
ternally consistent, countries that adopt financial neutrality
as a model of compensating donors, or the no-compensation
model, should prohibit the importation of any human
reproductive materials, for either reproductive or research
purposes, that are the product of commercial transactions.
The principle of ethical reciprocity and internal consistency
should always apply but, as we shall see, this is not always
the case.
Financial incentives: the market model
Financial incentives are benefits designed to incite a course
of action or to motivate an individual to respond, and as
such, they import relations of power. “They are best
understood as an alternative to other forms of power:
persuasion and coercion” (Grant and Sugarman, 2004). In the
research context, financial incentives aim to make research
participation more attractive to potential participants. They7 For example, Canada has adopted a system of altruistic donation
of human gametes for reproductive purposes, hence limiting
financial compensation to the reimbursement of direct and
receipted expenses. However, the importation of gametes is
allowed without consideration of the financial transactions that
led to the procurement of such gametes.are especially useful in the absence of other motives to
participate. Financial incentives characterize the market
model.
The economic principle of supply and demand governs this
model; therefore, financial incentives are determined by
what the market will bear. Given the increasing demand for
human reproductive materials for stem cell research, it is
conceivable that under this model (mirroring the current
market for human-assisted reproduction in countries like the
United States) (Spar, 2006; for contra-argument see Coving-
ton and Gibbons, 2007), oocyte providers will be paid
considerable sums as direct compensation for their contribu-
tion, in addition to indirect payment through completion
bonuses and other significant incentives. Furthermore, it is
plausible that a market model will systematically discourage
altruistic donations (Israni et al., 2005).
The market model is often used when the research or the
procurement is arduous and risky, offering little or no
prospect of direct benefit to the providers of biological
materials (e.g., oocyte procurement from nonmedical
volunteers). In these circumstances, the motivation to
participate in research or to contribute human reproductive
materials lies in the amount of financial incentive offered.
Consequently, the market model offers the advantage of
allowing providers to profit while making a socially beneficial
contribution. An additional advantage is that it encourages
high participation rates, thus ensuring a sufficient supply of
the oocytes necessary for research to progress.
Advocates of the market model argue that its major
advantage is that it promotes the liberty interests of
contributors and recipients. For them, “since most of our
free choices presuppose some control over our own bodies,
these liberty interests imply that people may even sell
parts of their body” (Resnik, 2001). Advocates further argue
that a public market prevents the emergence of a black
market and is not necessarily incompatible with the adoption
of safeguards that protect providers and donors (Thompson,
2007).
Certain features of this market model reveal its dis-
advantages. The monetary payments it offers could be
considered akin to undue inducement and, as such, have the
potential to compromise autonomous decision making and
taint the informed consent process by, for example,
diminishing the voluntariness of the consent or blurring the
understanding and/or the assessment of potential risks
involved. Furthermore, the market model could foster the
exploitation of economically vulnerable or disadvantaged
populations and, hence, violate social justice principles. Of
equal importance is the broader social impact of commodi-
fication on respect for human dignity and human rights. The
market approach thus appears incompatible with the
fundamental values that govern the donation of human
body parts (e.g., organs, cells, tissues) and as such it has
been condemned by most national and international organi-
zations, as well as professional societies (e.g., European
Society for Human Reproduction and Embryology Task Force
on Ethics and Law, 2007; Canadian Institutes of Health
Research, 2006; National Research Council and Institute of
Medicine of the National Academy of Sciences, 2004;
International Society for Stem Cell Research, 2007; European
Commission, Health and Consumer Protection Directorate
General, 2006).
8 In Australia, for instance, reasonable expenses includes “all
expenses related to supply and incurred in the collection, storage
and transport of the egg” (Australia, 2002). In contrast, the Czech
Republic extends the criterion of reasonable expenses to expenses
spent in relation to the procurement but allows taking into account
discomfort (Czech Republic, 2006).
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Compensation in general terms means rendering equivalent
for losses (e.g., financial, personal) sustained in a given sit-
uation. The goal of a compensation model is to redress a bal-
ance in terms of loss of expenditures and personal sacrifices. It
aims to protect donors from risk of death, bodily injury, loss of
time, inconvenience, or financial dislocation and, in so doing,
to encourage more potential donors to pursue their altruistic
impulses (Gaston et al., 2006). Under this model, the financial
compensation provided to donors ought not to be the
equivalent of payment. A reasonable amount to compensate
or reimburse donors signifies leaving them aswell off as before
donation; that is, it must be financially neutral. The higher the
level of compensation, the more it becomes morally proble-
matic or undesirable. Compensation can be further subdivided
into fixed or wage-payment approaches.
The fixed-compensation model
Under the fixed-compensation model, donors receive a
preestablished, standardized monetary payment, aiming at
compensating for the time, effort, and discomfort of
provision. In sharp contrast to the market model, the
fixed-compensation model allows only for small pecuniary
compensation set by public policy rather than by market
forces (Ethics Committee of the American Society for
Reproductive Medicine, 2007; United Kingdom, 2006; Aus-
tralia, 1995; Poland, 2005).
This model offers advantages and disadvantages. It pre-
vents monetary payments or inducement as the primary
motivation for contribution, while minimizing the financial
loss to the donors that is the direct consequence of the
contribution. However, it does not generate the potential for
mass recruitment within a short time (Israni et al., 2005), as
does the market model. Moreover, the amount of compensa-
tion is both fixed and capped and thus could lead to arbitrary
application. Yet, it provides the advantage of certainty and
fairness because every donor is treated the same way.
Provisions under this model are akin to the ones pertaining to
healthy volunteers in clinical research.
The wage-payment model
The rationale for the wage-payment model lies in a
conception of the procurement process as a form of unskilled
labor and, as such, allowing for the payment of providers
using a scale equal to a standardized, low, hourly wage (e.g.,
Finland). The model also allows for additional payments for
inconvenience and discomfort. Whereas it is in some respects
similar to the market model, the wage-payment model is not
governed by the economic principle of supply and demand;
rather the payment is set according to the unskilled-labor
market (Dickert and Grady, 1999).
The wage-payment model reduces the financial sacrifice
of oocyte providers. At the same time, the model provides an
incentive for people to contribute since wages are hourly
based. But the incentives provided are significantly less than
those granted under the market model.
While the model reduces the possibility of undue
inducement, it could lead to the disproportionate recruit-
ment of people with low incomes, which raises questions
regarding potential exploitation and fairness. Furthermore,
as providers are treated as unskilled workers, the model canbe challenged as a mechanism to promote the commercia-
lization of donor participation in research (Bentley and
Thacker, 2004). Finally, as the model assumes that research
participation is not significantly different in any substantial
moral sense from other forms of unskilled labor, the model
could be challenged on the grounds of its potential to breach
internationally accepted ethical principles and research
participant’s rights (e.g., right to withdraw).
The no-compensation model
Finally, any analysis of financial compensation models must
acknowledge the existence of models that propose no
compensation or recognition for the donor’s personal and
financial loss. The latter model rests on the belief that for a
donation to be truly altruistic, zero compensation should be
provided. Consequently, donors bear all the financial and
personal sacrifices associated with the donation (Israni et al.,
2005). To require pure altruism from oocyte donors is not only
unrealistic but also unfair (unless so desired by the donor).
Oocyte donors are subject to a battery of questionnaires,
invasive tests, hyperstimulation, and retrieval methods. This
model fails to recognize the necessary personal, health, and
financial costs involved in the donation and essentially
penalizes donors for their gift. The model also fails to
acknowledge the vital societal contribution donors make by
helping to advance science. However, this is the only model
that lacks all the negative features of themarket model, such
as commercialization or the creation of markets.
The expense-reimbursement model
Reimbursement of expenses incurred in connection with
research participation or donation could be considered a
form of compensation broadly understood; we opted for
subdividing them for methodological purposes.
The most commonly adopted model is the expense-reim-
bursement model. (Canada, Cyprus, Finland, France, Japan,
Singapore, South Africa, South Korea, and the United King-
dom have all implemented this model.) The rationale
underlying this model is the prevention of financial profit
from donation, while compensating donors for any financial
sacrifice incurred in direct relation to the donation (Dickert
and Grady, 1999).
Several methods for reimbursing donors exist under this
model (Israni et al., 2005). One approach favors reimbursing
donors only for expenditures such as travel, meals, daycare,
parking, and lodging, while other methods allow donors to be
compensated for loss of wages (e.g., Finland, 2001a, 2001b;
United Kingdom, 2006). All preclude donors from being
compensated for nonfinancial expenses such as effort, pain,
and discomfort. Additionally, a variety of qualifiers serve to
distinguish the approaches taken by different countries with
regard to regulating this model. Those qualifiers require that
the reimbursement be limited to “reasonable expenses”8 or to
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consideration” (e.g., New Zealand, 2004; Singapore, 2004).
While the expense-reimbursement model reduces ethical
concerns about undue inducement, especially toward vul-
nerable populations, it could lead to unequal payment of
donors for the same type of participation; a subject earning
higher wages would receive more compensation than
subjects with lower incomes or those who are unemployed.
Additionally, the model provides very limited incentive for
people to donate and could create a financial burden for
donors not reimbursed for lost wages (e.g., France, 2004) or
for time away from work or where reimbursement is limited
to receipted expenses only (e.g., Canada, 2004). Paradoxi-
cally, although it occupies the moral high ground in today’s
debate, this “proven expenses only” approach could, like the
no-compensation model, result in commercial exploitation
through forum shopping or a black market. Additionally, the
administrative proof required of donors and clinics could be
burdensome. Moreover, considering the heightened concern
for quality assurance and traceability of human reproductive
materials, the even narrower receipted-expenses-only policy
could in the long term further reduce the availability of
human reproductive materials.
Nevertheless, the model preserves altruism as the
primary motivation for donation, and this in itself is
valuable. Thus, if compensation includes the reimbursement
of reasonable expenses (including loss of wages) that are
directly connected to the donation, donors are not receiving
“valuable consideration” or financial profit, nor are they
being exploited (Bentley and Thacker, 2004). Rather, they
are receiving a token of appreciation as a symbolic
recognition for their services to society.
Conclusion
In light of the above, perhaps a more equitable solution
would be to develop a mixed model wherein there is a
statutorily determined amount offered. This set amount
would, however, distinguish between the types of reproduc-
tive material (Knoppers et al., 2007) and the accompanying
risks and personal effort. Across the board, the set amount of
monetary payment would be determined by a competent
authority9 that would take into account the time, effort, and
risks involved in donation while also offering insurance10
(Israni et al., 2005) for donors to cover potential complica-
tions arising from the donation (e.g., bodily injury).9 A detailed analysis of our proposal is outside the scope of this
paper. Suffice it to say that we recommend that, following the
approach adopted in several jurisdictions (e.g., Victoria, Australia;
Israel; United Kingdom), the statutory amount should be established
by a regulatory or licensing national authority. Thus we disagree with
the recommendation of the International Society for Stem Cell
Research (2007) with respect to compensation levels being deter-
mined by local oversight committees on a case-by-case basis. Our
position is based, among other reasons, on consideration of social
justice, certainty, and concerns over the potential for exploitation of
the vulnerable, arbitrary applications, and lack of transparency.
10 Our proposal for providing insurance to donors should not be
constructed as for financial gain but rather it should be considered
an appropriate hedge against uncertain health risks.The statutory amount would have a dual purpose: to act
as a financial incentive to encourage donation and to act
as a financial compensation for personal and financial
sacrifices. The modest statutory amount would be
capped11 and also be below what proponents of the
markets would propose (e.g., completion bonuses will be
prohibited) to lessen concerns over exploitation or undue
inducement. Furthermore, if the monetary amount is low,
the undesirable commercialization of the research process
could be prevented. Obviously (although beyond the scope
of this article), the adoption of this approach requires a
reconsideration of the schemes governing organ and blood
donation as well.
Furthermore, by linking compensation to risk, our pro-
posal preserves the essence of donation as a gift. The amount
would still largely remain a symbolic recognition of the true
value of such participation in stem cell research. This
proposed mixed model respects altruism, solidarity, and
the liberty interests of donors. It is based on principles and
pragmatism. It offers certainty, transparency, and fairness.
We acknowledge that at least some potential donors
would still be influenced by the monetary payment regard-
less of its size. Hence, our proposed model would not resolve
the challenge of overrepresentation of vulnerable popula-
tions and its negative consequences in terms of diminishing
the integrity of the research. Consequently, the use of
monetary payments as an incentive to encourage donor
participation in research can be justified only in the context
of a comprehensive and effective system of research donor
protections.
Furthermore, given the international realities of stem cell
research, global recognition is necessary to prevent “ethical
arbitrage” or forum shopping. Several jurisdictions, albeit
with different conceptualizations of monetary payments,
have led the way by prohibiting the importation of gametes
and stem cell lines that have not been procured in
accordance with the local laws governing monetary pay-
ments and consent rules (e.g. California, 2006; Czech
Republic, 2006). These jurisdictions, by setting political
and ethical boundaries, demonstrate that a society is
capable of making ethical assessments, encouraging consis-
tency, and establishing priorities.
Offering monetary payments to oocyte donors does not
automatically lead to the commodification of human
gametes or to undue inducement, exploitation, or coercion
of donors. Removing fair compensation from the picture does
not in turn prevent any of these problems from occurring. But
as history has shown, regulatory vacuums and the lack of
adequate procedural and substantive safeguards undeniably
lead to abuse.
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